Want to see HK:2096 full AI Analyst Report?
2096 Stock Chart & Stats
HK$11.60
-HK$0.02(-0.30%)
At close: 4:00 PM EST
HK$11.60
-HK$0.02(-0.30%)
Day’s Range― - ―
52-Week RangeHK$9.07 - HK$14.38
Previous CloseN/A
Volume1.11M
Average Volume (3M)4.06M
Market Cap
HK$26.04B
Enterprise ValueHK$23.39B
Total Cash (Recent Filing)HK$4.06B
Total Debt (Recent Filing)HK$2.44B
Price to Earnings (P/E)14.1
Beta0.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.04%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,568,198,700
10 Day Avg. Volume4,876,410
30 Day Avg. Volume4,062,607
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.84
Price to Sales (P/S)3.46
P/FCF Ratio23.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.77Price Target Upside61.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationRevenue expansion resumed meaningfully in 2025 after a nearly flat 2024, indicating renewed commercial momentum across the pharmaceutical portfolio. If maintained, this growth can broaden the earnings base, support reinvestment in specialty medicines, and strengthen the company’s position in China’s healthcare channels.
High ProfitabilityThe exceptionally high gross margin provides substantial economic value from product sales, while the recovery in net margin shows improved conversion of revenue into earnings. This profitability supports internal funding for research, commercialization, and continued development of higher-value medicines.
Conservative Balance SheetA materially lower debt-to-equity ratio gives Simcere greater financial flexibility and reduces the balance-sheet burden associated with funding its operations. Rising return on equity also indicates that the company is using its enlarged equity base more effectively, supporting durable shareholder value creation.
Bears Say
Uneven Cash ConversionAlthough recent cash generation improved, negative free cash flow in multiple prior years and only partial conversion of 2025 earnings into free cash flow indicate uneven earnings quality. This may constrain the consistency of internally funded investment, distributions, and debt servicing over time.
Earnings Margin VolatilityThe substantial movement in net margin shows that profitability has not followed a consistently stable trajectory, despite the strong 2025 recovery. Such variability makes future earnings power less predictable and suggests that product mix or operating outcomes can materially affect results across reporting periods.
Meaningful Absolute DebtLow leverage is a strength, but the remaining absolute debt balance still creates obligations that must be supported by operating cash generation. Because cash flow has been volatile historically, weaker conversion in a future period could reduce financial flexibility even without a major change in leverage.
Simcere Pharmaceutical Group Limited News
2096 FAQ
What was Simcere Pharmaceutical Group Limited’s price range in the past 12 months?
Simcere Pharmaceutical Group Limited lowest stock price was HK$9.07 and its highest was HK$14.38 in the past 12 months.
What is Simcere Pharmaceutical Group Limited’s market cap?
Simcere Pharmaceutical Group Limited’s market cap is HK$26.04B.
When is Simcere Pharmaceutical Group Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Simcere Pharmaceutical Group Limited’s earnings last quarter?
Currently, no data Available
Is Simcere Pharmaceutical Group Limited overvalued?
According to Wall Street analysts Simcere Pharmaceutical Group Limited’s price is currently Undervalued.
Does Simcere Pharmaceutical Group Limited pay dividends?
Simcere Pharmaceutical Group Limited pays a Annually dividend of HK$0.207 which represents an annual dividend yield of 2.04%. See more information on Simcere Pharmaceutical Group Limited dividends here
What is Simcere Pharmaceutical Group Limited’s EPS estimate?
Simcere Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Simcere Pharmaceutical Group Limited have?
Simcere Pharmaceutical Group Limited has 2,568,198,700 shares outstanding.
What happened to Simcere Pharmaceutical Group Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Simcere Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:2096
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Simcere Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$18.77 (61.77% Upside)
HK$18.77 (61.77% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.60%
12-Months-Change
Fundamentals
Return on Equity
16.54%
Trailing 12-Months
Asset Growth
29.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
2096 Stock 12 Month Forecast
Average Price Target
HK$18.77
▲(61.77% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Shanghai Henlius Biotech, Inc. Class H
―